Welcome to our dedicated page for Cvs Health news (Ticker: CVS), a resource for investors and traders seeking the latest updates and insights on Cvs Health stock.
CVS Health Corporation operates an integrated health care model that combines retail pharmacy, pharmacy benefit management, health insurance, medical clinics, specialty and mail pharmacy support, and related consumer health services. Recurring company news includes quarterly results and guidance, segment performance across Health Services, Health Care Benefits, and Pharmacy & Consumer Wellness, and capital returns through common-stock dividends.
Updates also cover CVS Caremark formulary decisions, biosimilar adoption, Aetna prior authorization and plan-administration initiatives, community health investments by the CVS Health Foundation, and developments involving Omnicare, the company's long-term care pharmacy subsidiary.
CVS Health (NYSE:CVS) announced a $2.24 million investment in Health Impact Ohio to launch a Health Zone in Columbus on March 10, 2026. The funding expands Community Health Worker capacity, maternal and behavioral health services, training and data systems to reduce avoidable emergency care and improve care coordination.
The investment builds on CVS's broader Ohio footprint, including workforce centers, affordable housing investments (~$80 million) and reported FY2024 economic contributions.
CVS Health (NYSE: CVS) and Google Cloud announced a strategic partnership to launch Health100, an AI-native consumer engagement platform aimed at creating a connected, proactive, and personalized health experience. The platform will use Google Cloud technologies including Gemini models, Cloud Healthcare API, and BigQuery.
Health100 is designed to enable real-time, omni-channel support, pharmacist-led care management, cost transparency, and future biometric wearable integration. Initial launch is planned for 2026 with a first look at The Check Up in March 2026.
CVS (NYSE:CVS) became an Official Health and Wellness Partner of the U.S. Soccer Federation and the National Women's Soccer League on Feb 19, 2026, backing a multi-year program to develop community multi-use soccer fields in select U.S. markets through 2028.
The sponsorship also includes club partnerships with Washington Spirit, Seattle Reign FC and Kansas City Current and community programs amplified by athletes and ambassadors.
CVS Health (NYSE: CVS) announced a $5 million scholarship program to support students pursuing a Doctor of Pharmacy (PharmD) at Xavier University of Louisiana and the University of Louisiana at Monroe.
The program aims to reduce financial barriers, strengthen Louisiana's pharmacy workforce, and expand access to care, starting in the 2026-27 academic year.
CVS Health (NYSE: CVS) reported fourth-quarter and full-year 2025 results with total revenues of $105.7B (Q4, +8.2% YoY) and a record $402.1B for the year (+7.8% YoY). GAAP diluted EPS was $2.30 in Q4 and $1.39 for the year; adjusted EPS was $1.09 in Q4 and $6.75 for the year.
The company generated $10.6B of operating cash flow in 2025, completed pharmacy reimbursement transitions, and cited $5.7B goodwill impairment and ~$1.2B legacy litigation charges that reduced operating income. 2026 adjusted EPS guidance: $7.00–$7.20; GAAP EPS guidance: $5.94–$6.14.
CVS (NYSE: CVS) announced that about 9,000 CVS Pharmacy locations now accept TrumpRx discount cards, allowing eligible patients to apply manufacturer-determined savings at the pharmacy counter.
CVS notes its 27,000 community pharmacists can help customers, and that CVS Specialty and NovoCare support reduced pricing for fertility medications via the TrumpRx Fertility program.
Aetna (NYSE: CVS) was named Press Ganey's inaugural Health Plan of the Year at the Human Experience (HX26) Conference on Feb. 5, 2026. The award recognizes sustained excellence in member experience, quality performance and provider collaboration, citing programs like the HX Exchange partnership with Press Ganey.
CVS (NYSE: CVS) will add osteoporosis biosimilars Ospomyv and Stoboclo and generic teriparatide (Bonsity, Tymlos) to major national commercial template formularies effective April 1, 2026, replacing Prolia and Forteo to expand lower-cost options.
The preferred biosimilar approach is stated to be over 50% lower cost per prescription; CVS Caremark cites $1.5 billion in gross savings to date and a 96% Humira-to-biosimilar transition rate for client members.
Aetna (NYSE: CVS) announced a fully digital benefits onboarding experience for four million members for the 2026 welcome season on Feb. 5, 2026. The program uses enhanced messaging, moving from SMS to RCS, to reduce clicks and avoid mandatory app downloads.
Aetna reported an 80% increase in member engagement and a 26% reduction in opt-out rates for RCS-supported interactions and plans to expand RCS across discharge, recovery, and chronic condition management in 2026.
CVS Health (NYSE: CVS) is activating emergency measures ahead of a major winter storm expected to affect much of the U.S. over the next few days. The company is urging pharmacy patients to refill and pick up prescriptions and is supplying stores with extra emergency items such as water, batteries and first aid products.
CVS Caremark is enabling one-time emergency 10-day refills where states have declared emergencies. CVS Specialty and Aetna clinical teams will contact impacted patients and members to arrange alternate deliveries and expanded access to emergency care and mental health support. Store closures will follow local orders and phone lines will be rerouted as needed.